SAREPTA THERAPEUTICS, INC. (SRPT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 1.40B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.40B | (m) | (m) |
| 2026-03-31 | (m) | $1.58B | (m) | (m) |
| 2025-12-31 | $1.02B | $1.86B | (m) | 54.96% |
| 2025-09-30 | (m) | $2.13B | (m) | (m) |
| 2025-06-30 | (m) | $2.19B | (m) | (m) |
| 2025-03-31 | (m) | $2.04B | (m) | (m) |
| 2024-12-31 | (m) | $1.79B | (m) | (m) |
| 2024-09-30 | (m) | $1.51B | (m) | (m) |
| 2024-06-30 | (m) | $1.39B | (m) | (m) |
| 2024-03-31 | (m) | $1.27B | (m) | (m) |
| 2023-12-31 | (m) | $1.14B | (m) | (m) |
| 2023-09-30 | (m) | $1.02B | (m) | (m) |
| 2023-06-30 | (m) | $914.19M | (m) | (m) |
| 2023-03-31 | (m) | $886.44M | (m) | (m) |
| 2022-12-31 | (m) | $843.77M | (m) | (m) |
| 2022-09-30 | (m) | $786.56M | (m) | (m) |
| 2022-06-30 | (m) | $745.70M | (m) | (m) |
| 2022-03-31 | (m) | $676.30M | (m) | (m) |
| 2021-12-31 | (m) | $612.40M | (m) | (m) |
| 2021-09-30 | (m) | $556.32M | (m) | (m) |
| 2021-06-30 | (m) | $510.84M | (m) | (m) |
| 2021-03-31 | (m) | $480.34M | (m) | (m) |
| 2020-12-31 | (m) | $455.87M | (m) | (m) |
| 2020-09-30 | (m) | $433.33M | (m) | (m) |
| 2020-06-30 | (m) | $410.95M | (m) | (m) |
| 2020-03-31 | (m) | $394.27M | (m) | (m) |
| 2019-12-31 | (m) | $380.83M | (m) | (m) |
| 2019-09-30 | (m) | $365.13M | (m) | (m) |
| 2019-06-30 | (m) | $344.58M | (m) | (m) |
| 2019-03-31 | (m) | $323.44M | (m) | (m) |
| 2018-12-31 | (m) | $301.03M | (m) | (m) |
| 2018-09-30 | (m) | $273.90M | (m) | (m) |
| 2018-06-30 | (m) | $241.36M | (m) | (m) |
| 2018-03-31 | (m) | $202.85M | (m) | (m) |
| 2017-12-31 | (m) | $154.58M | (m) | (m) |
| 2017-09-30 | (m) | $102.73M | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.42M | (m) | (m) |
| 2015-12-31 | (m) | $1.25M | (m) | (m) |
| 2014-12-31 | (m) | $9.76M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |